Events

Videos

Podcasts

Articles

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Other Promising Targets in TNBC

Role of the Androgen Receptor in TNBC

Combination Therapy for TNBC: Checkpoint Inhibitor + Chemotherapy

Checkpoint Inhibitor Monotherapy for TNBC

Antibody-Drug Conjugates in Treating TNBC

Paclitaxel vs Nab-Paclitaxel in Metastatic TNBC

No pCR in Patients After Neoadjuvant Chemotherapy in TNBC

Anthracycline-Based Regimens: Perioperative Setting for TNBC

Neoadjuvant Therapy in TNBC

Combining PARP Inhibitors + Checkpoint Inhibitors in TNBC

Sequencing in BRCA-Positive TNBC Patients

NCCN Guideline Changes for BRCA Testing in TNBC

Germline BRCA Mutations in TNBC

Histologic Subtyping in TNBC

Classification of Triple Negative Breast Cancer

Bristol-Myers Squibb and Nektar Therapeutics have announced plans to jointly develop and market combinations of the CD122-biased cytokine NKTR-214 with nivolumab (Opdivo) or nivolumab plus ipilimumab (Yervoy) across for 20 indications in 9 tumor types.

Bristol-Myers Squibb Gains NKTR-214 Access in Nektar Collaboration

Thomas Powles MBBS, MRCP, MD, discusses the findings from the CheckMate-214 trial, as well as continuing studies in immunotherapy and targeted therapy in kidney cancer.

Powles Sheds Light on Shifting Landscape in Kidney Cancer

Several phase III studies are exploring immunotherapy combinations with the potential to disrupt the systemic treatment paradigm for patients with ovarian cancer. 

Immunotherapy Combos on Horizon for Ovarian Cancer

Rebecca C. Arend, MD, discussed novel combinations being investigated for the treatment of patients with ovarian cancer.

PARP Combos With Bevacizumab, Immunotherapy in Development for Ovarian Cancer Treatment

Two-year follow-up data showed sustained improvements in overall survival with pembrolizumab over chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer.

Pembrolizumab Survival Benefit Sustained in 2-Year Urothelial Cancer Data

Immuno-Oncology

Immuno-Oncology | Specialty